Vertex EVP sells shares in planned stock sale

Vertex Pharmaceuticals executive Jonathan Biller reported share sales and tax-related share dispositions.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Jonathan Biller reported share sales and tax-related share dispositions. On 02/11/2026, he sold 1,925 shares of Vertex common stock in an open-market transaction at $460.43 per share under a company-approved Rule 10b5-1 trading plan.

On 02/10/2026, 1,630 shares were disposed of at $468.41 per share to satisfy tax obligations by delivering shares. Following these transactions, Biller directly owned 20,819 shares of Vertex common stock.

Insider Trade Summary

Net Seller: 1,925 shares

Net Sell 2 txns

Insider Biller Jonathan

Role EVP and Chief Legal Officer

Sold 1,925 shs ($886K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,925	$460.43	$886K
Exercise Price or Tax Liability	Common Stock	1,630	$468.41	$764K

Holdings After Transaction: Common Stock — 20,819 shares (Direct)

Footnotes (1)

1. F1. Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did VRTX executive Jonathan Biller report?

Jonathan Biller reported an open-market sale of 1,925 shares of Vertex common stock at $460.43 per share, plus a separate disposition of 1,630 shares at $468.41 per share to cover tax obligations by delivering shares instead of paying cash.

How many VRTX shares did Jonathan Biller sell in the open market?

Jonathan Biller sold 1,925 shares of Vertex Pharmaceuticals common stock in an open-market transaction at a price of $460.43 per share. This transaction was reported as a sale code "S" under Section 16 rules for non-derivative securities of Vertex.

Was Jonathan Biller’s VRTX stock sale under a Rule 10b5-1 plan?

Yes. The Form 4 notes that the transaction was made under Mr. Biller’s company-approved trading plan established pursuant to SEC Rule 10b5-1, which was entered into on February 24, 2025, providing a pre-arranged schedule for selling shares.

Why were 1,630 VRTX shares disposed of by Jonathan Biller?

The 1,630 Vertex shares were disposed of to satisfy tax liabilities by delivering securities, a transaction type coded "F". This method allows withholding shares instead of paying taxes in cash when equity awards vest or are exercised by the executive.

How many VRTX shares does Jonathan Biller own after these transactions?

After the reported transactions, Jonathan Biller directly owned 20,819 shares of Vertex common stock. This figure reflects both the 1,925-share open-market sale and the 1,630-share tax-withholding disposition, as disclosed in the beneficial ownership column on the Form 4.

What is Jonathan Biller’s role at Vertex Pharmaceuticals (VRTX)?

Jonathan Biller serves as Executive Vice President and Chief Legal Officer at Vertex Pharmaceuticals. His position is identified in the Form 4, which also confirms he is an officer but not a director or ten-percent owner of the company’s outstanding common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 04:52 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Biller Jonathan

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		F		1,630	D	$468.41	22,744	D
Common Stock	02/11/2026		S(1)		1,925	D	$460.43	20,819	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.